Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | ABL1 | P00519 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | PKM | P14618 | 1/20 | 0.97 |
| ▸ | IDE | P14735 | 1/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.97 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.97 |
| ▸ | HLCS | P50747 | 6/20 | 0.68 |
| ▸ | CA12 | O43570 | 7/20 | 0.55 |
| ▸ | CA1 | P00915 | 7/20 | 0.55 |
| ▸ | CA2 | P00918 | 7/20 | 0.55 |
| ▸ | CA9 | Q16790 | 7/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Biotin SCHEMBL3473268 | 1.00 | TDP1 (0.97) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL36572 | 0.99 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL410686 | 0.99 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL3384633 | 0.99 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL9841217 | 0.99 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL23055065 | 0.99 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL21981206 | 0.99 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL20547409 | 0.99 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL22943835 | 0.99 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM | |
| Biotin SCHEMBL59420 | 0.99 | TDP1 (1.00) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110819614-B | Method for improving driving force of enzyme-driven micro-nano motor | 武汉理工大学 | 2023-04-11 | — | — | CN | claimed |
| CN-110438074-A | A kind of immunocyte recovery culture solution and preparation method thereof | GUANGZHOU SHAAI BIOLOGICAL TECH CO LTD | 2019-11-12 | — | — | CN | claimed |
| CN-106967213-A | Eight-arm polyethylene glycol, preparation method, functionalized derivative and modified biologically-relevant substance | 厦门赛诺邦格生物科技股份有限公司 | 2017-07-21 | — | — | CN | claimed |
| US-20060222588-A1 | Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent | GLYCOREX TRANSPLANTATION AB (SE) | 2006-10-05 | — | — | US | claimed |
| US-20050191682-A1 | Methods for fragmenting DNA | AFFYMETRIX, INC. (US) | 2005-09-01 | — | — | US | claimed |
| EP-1564306-A2 | Methods for fragmenting and labeling DNA | Affymetrix, Inc. (US) | 2005-08-17 | — | — | EP | claimed |
| US-20250353886-A1 | Modification and Compositions of Human Secretoglobin Proteins | APC RES ASSETS LLC (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250339542-A1 | CONVERSION OF A BIOLOGICALLY SILENT MIRNA BINDING SMALL MOLECULE TO AN MIRNA DEGRADER | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-11-06 | — | — | US | disclosed |
| WO-2025054616-A1 | PLATFORM APPROACH F-18 RADIOLABELING OF VARIOUS PEPTIDES IN AQUEOUS MEDIUM | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2025-03-13 | — | — | WO | disclosed |
| US-20240239818-A1 | COMPOUNDS AND COMPOSITIONS COMPRISING FLUOROPHORES FOR USE IN VISUALIZATION AND PURIFICATION OR MANIPULATION | HOWARD HUGHES MEDICAL INSTITUTE | 2024-07-18 | — | — | US | disclosed |
| CN-111065417-B | Immunogenic compositions | 美商艾芬尼维克斯公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-4327876-A2 | IMMUNOGENIC COMPOSITIONS | Affinivax, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20230414740-A1 | IMMUNOGENIC COMPOSITIONS | AFFINIVAX, INC. | 2023-12-28 | — | — | US | disclosed |
| US-5976535-A | ADMINISTERING A FIRST CONJUGATE COMPRISING A TARGETING MOIETY AND STREPTAVIDIN; AND SUBSEQUENTLY ADMINISTERING A SECOND CONJUGATE COMPRISING A CYTOKINE AND BIOTIN, REDUCING THE ENDOGENOUS BIOTIN LEVEL | NEORX CORPORATION (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0733066-A4 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORP (US) | 1999-04-21 | — | — | EP | disclosed |
| WO-1998021521-A1 | TWO-PHOTON OR HIGHER-ORDER ABSORBING OPTICAL MATERIALS AND METHODS OF USE | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1998-05-22 | — | — | WO | disclosed |
| EP-0733066-A1 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995015979-A1 | PRETARGETING METHODS AND COMPOUNDS | NEORX CORPORATION (US) | 1995-06-15 | — | — | WO | disclosed |
| EP-0526587-A1 | MODIFICATION OF POLYMER SURFACES BY TREATMENT WITH Ce(IV) SALTS AND ELECTROMAGNETIC RADIATION | NOVO NORDISK A/S (DK) | 1993-02-10 | — | — | EP | disclosed |
| WO-1991016377-A1 | MODIFICATION OF POLYMER SURFACES BY TREATMENT WITH Ce(IV) SALTS AND ELECTROMAGNETIC RADIATION | NOVO NORDISK A/S (DK) | 1991-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239818-A1 | COMPOUNDS AND COMPOSITIONS COMPRISING FLUOROPHORES FOR USE IN VISUALIZATION AND PURIFICATION OR MANIPULATION | STAMBP, MSN, SYPL1 | TDP1 2926/4885MEN1 3796/4885ABL1 1651/4885 |
| US-20250339542-A1 | CONVERSION OF A BIOLOGICALLY SILENT MIRNA BINDING SMALL MOLECULE TO AN MIRNA DEGRADER | NSUN3, AGO2, ZFR | TDP1 1666/4885MEN1 1716/4885ABL1 4245/4885 |
| US-20060222588-A1 | Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent | CD47, CD40, TNFSF11 | TDP1 2602/4885MEN1 798/4885ABL1 791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.